Related Experiment Video
Updated: Jul 11, 2026
09:54
Laboratory Scale Production and Purification of a Therapeutic Antibody
Published on: January 24, 2017
The future of antibody therapy
1Therapeutic Human Polyclonals Inc., 2105 Landings Drive, 94043, Mountain View, USA. rolandbuelow@aol.com
Ernst Schering Foundation Symposium Proceedings
|September 11, 2007
Summary
Polyclonal antibodies (pAbs) offer a potent therapeutic alternative to monoclonal antibodies (mAbs), overcoming limitations and enabling new production technologies for treating various diseases.
Area of Science:
- Immunology
- Biotechnology
- Therapeutics
Background:
- Antibodies have been utilized as therapeutics for over a century.
- Therapeutic monoclonal antibodies (mAbs) have shown efficacy but also limitations.
- Combinations of mAbs or polyclonal antibody (pAb) preparations can overcome these limitations.
Purpose of the Study:
- To explore the potential of polyclonal antibodies (pAbs) as therapeutics.
- To highlight advancements in pAb production technologies.
- To demonstrate the broad applicability of pAbs in treating diseases.
Main Methods:
- Review of existing studies on mAb and pAb therapeutics.
- Analysis of novel technologies for producing human pAbs in genetically engineered animals.
- Evaluation of pAb efficacy and safety in preclinical and clinical settings.
Main Results:
- Polyclonal antibodies (pAbs) derived from human and animal plasma are effective and safe therapeutic agents.
- New technologies facilitate the production of human pAbs in engineered animals.
- High-titer pAb preparations can be generated for various therapeutic applications.
Conclusions:
- Polyclonal antibodies (pAbs) represent a viable therapeutic strategy, addressing limitations of monoclonal antibodies (mAbs).
- Advancements in production, including genetically engineered animals, promise effective and safe high-titer antibody preparations.
- pAbs hold significant potential for treating infectious diseases, cancer, and autoimmune disorders.
More Related Videos
Related Concept Videos
01:31Hybridoma Technology
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
01:26Antibody Actions
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
01:10Antibody Structure
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
01:25Antibody Structure and Classes
Antibodies, also known as immunoglobulins, are produced by B cells in response to foreign substances, such as bacteria and viruses. These proteins are critical for recognizing and neutralizing these substances, protecting the body from potential harm.
The basic structure of an antibody consists of four protein chains: two identical heavy chains and two identical light chains. These chains are held together by disulfide bonds and other non-covalent interactions, forming a Y-shaped structure.
The basic structure of an antibody consists of four protein chains: two identical heavy chains and two identical light chains. These chains are held together by disulfide bonds and other non-covalent interactions, forming a Y-shaped structure.
01:29Microorganisms in Medicine and Therapeutics
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
01:36Humoral Immune Responses
Overview